Physician profile
Robert D Burgos
NPI 1952359135
$5,188.36
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $891 · 2021: $1,407 · 2022: $1,411 · 2023: $1,019 · 2024: $69.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,560.14 | 2019-2024 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,352.01 | 2019-2023 | Trulance, Xifaxan |
| Ironwood Pharmaceuticals, INC | $840.25 | 2019-2024 | Linzess |
| Janssen Biotech, INC. | $380.57 | 2019-2023 | Stelara, Simponi Aria, Simponi |
| Braintree Laboratories, INC. | $253.97 | 2019-2024 | Suflave, Sutab |
| Redhill Biopharma INC. | $214.45 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Nestle Healthcare Nutrition INC. | $148.80 | 2021-2023 | |
| Ethicon US, LLC | $61.22 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $58.83 | 2021-2023 | Clenpiq |
| Takeda Pharmaceuticals U.S.A., INC. | $56.82 | 2020-2021 | |
| Vivus LLC | $53.32 | 2021-2022 | |
| Qol Medical, LLC | $46.42 | 2022 | |
| Celgene Corporation | $40.77 | 2021-2023 | Zeposia |
| Ucb, INC. | $34.07 | 2019 | |
| Evoke Pharma, INC. | $31.12 | 2021-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.24 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $16.46 | 2023 | Voquezna |
| Intercept Pharmaceuticals, INC. | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Burgos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.